Form 8-K ViewRay, Inc. For: Aug 15
Tweet
Share
E-mail
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 15, 2016
VIEWRAY, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
Delaware |
|
001-37725 |
|
42-1777485 |
|
(State or Other Jurisdiction of Incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer Identification Number) |
2 Thermo Fisher Way
Oakwood Village, Ohio 44146
(Address of principal executive offices, including zip code)
(440) 703-3210
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
On August 15, 2016, ViewRay, Inc. issued a press release announcing its financial results for the fiscal quarter ended June 30, 2016. The press release is attached hereto as Exhibit 99.1.
The information in this Item 2.02 of this Current Report on Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), or incorporated by reference in any filing of ViewRay, Inc. under the Securities Act or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 7.01Regulation FD Disclosure.
The information set forth under Item 2.02 of this Current Report on Form 8-K is incorporated by reference into this Item 7.01.
The information in this Item 7.01 of this Current Report on Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), or incorporated by reference in any filing of ViewRay, Inc. under the Securities Act or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Item 9.01Financial Statements and Exhibits.
(d) Exhibits.
|
ExhibitNumber |
Description |
|
99.1 |
Press Release dated August 15, 2016. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
VIEWRAY, INC.
|
Dated: August 15, 2016 |
By:/s/ Chris A. Raanes |
EXHIBIT INDEX
|
ExhibitNumber |
Description |
|
99.1 |
Press Release dated August 15, 2016. |
Exhibit 99.1
ViewRay Reports Second Quarter 2016 Financial Results
Company expects to submit MRIdian linac technology for FDA 510(k) clearance and CE Mark by end of 2016
Recent Highlights:
|
|
· |
Received 3 new orders for MRIdian Systems, totaling $17.1 million; shipped one system |
|
|
· |
Total backlog of $100.7 million, representing 18 signed sales contracts, as of June 30, 2016 |
|
|
· |
Extended cash runway with $15.0 million from term loan facility in May |
|
|
· |
Unique abilities of MRIdian to treat cancer patients were highlighted in 3 separate TV segments |
|
|
· |
ViewRay’s MRIdian System Receives Japanese Regulatory Approval (Shonin) |
CLEVELAND, August 15, 2016 — ViewRay, Inc. (Nasdaq: VRAY) today announced financial results for the second quarter and six months ended June 30, 2016.
“We are making exciting progress, highlighted by the continued development of our MRIdian linac technology. During site visits to assess the technology, clinicians and scientists have commented that they are particularly impressed by the sharpness of the beam and the high dose rate,” said Chris A. Raanes, President and Chief Executive Officer of ViewRay. “Recently, we presented the first technical data on the capabilities of MRIdian linac technology at the American Association of Physicists in Medicine in Washington DC. We anticipate presenting additional data on the MRIdian linac technology at the American Society for Radiation Oncology (ASTRO) annual meeting in September. We are on track with our linac development program and anticipate submitting for FDA 510(k) clearance and CE Mark in Europe by the end of the year.”
Mr. Raanes added, “We received three new orders in the second quarter, including our first order at a prestigious academic institution in Manhattan. As of June 30, 2016 our backlog exceeded $100 million, representing 18 signed sales contracts. We also shipped one MRIdian System in the quarter that we anticipate will be recognized as revenue upon completion of installation. The unique abilities of the MRIdian System were recently highlighted in three different television segments.” These stories can be viewed on ViewRay’s website at http://www.viewray.com/in-the-news.
Financial Results
Total revenue for the fiscal quarter ended June 30, 2016 was $0.3 million, compared to $0.2 million for the same period last year. Total revenue for the six months ended June 30, 2016 was $5.8 million, compared to $0.5 million for the same period last year.
Cost of product revenue was $0.1 million for the fiscal quarter ended June 30, 2016, compared to $0.4 million for the same period last year. Total gross profit (loss) for the fiscal quarter ended June 30, 2016 was $(0.6) million, compared to $(0.7) million for the same period last year. Cost of product revenue was $6.1 million for the six months ended June 30, 2016, compared to $0.5 million for the same period last year. Total gross profit (loss) for the six months ended June 30, 2016 was $(1.6) million, compared to $(1.1) million for the same period last year.
Total operating expenses for the fiscal quarter ended June 30, 2016 were $10.2 million, compared to $10.7 million for the same period last year. Total operating expenses for the six months ended June 30, 2016 were $21.2 million, compared to $18.2 million for the same period last year.
Net loss for the second quarter ended June 30, 2016 was $(12.1) million, or $(0.32) per share, compared to $(12.2) million, or $(13.24) per share for the same period last year. Net loss for the six months ended June 30, 2016 was $(25.5) million, or $(0.67) per share, compared to $(20.6) million, or $(22.52) per share, for the same period last year.
ViewRay had total cash and cash equivalents of $9.4 million at June 30, 2016. In May 2016, ViewRay borrowed $15.0 million under its Term Loan Agreement with CRG.
Exhibit 99.1
ViewRay will hold a conference call on Monday, August 15, 2016 at 4:30 p.m. ET / 1:30 p.m. PT to discuss the results. The dial-in numbers are 844-277-1426 for domestic callers and 336-525-7129 for international callers. The conference ID number is 60847362. A live webcast of the conference call will be available on the investor relations page of ViewRay’s corporate website at www.viewray.com.
After the live webcast, a replay of the webcast will remain available online on the investor relations page of ViewRay’s corporate website, www.viewray.com, for 90 days following the call. In addition, a telephonic replay of the call will be available until August 22, 2016. The replay dial-in numbers are 855-859-2056 for domestic callers and 404-537-3406 for international callers. Please use the replay pin number 60847362.
About ViewRay
ViewRay®, Inc. (Nasdaq: VRAY) designs, manufactures and markets the MRIdian® radiation therapy system. MRIdian integrates MRI technology, radiation delivery and proprietary software to locate, target and track the position and shape of soft-tissue tumors during radiation. ViewRay believes this combination of enhanced visualization and accuracy will significantly improve outcomes for patients.
The MRIdian linac is a technology under development and not available for sale or distribution in the United States. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
Forward Looking Statements:
This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to filing for regulatory approval of ViewRay’s MRIdian linac technology in the second half of 2016, the development of ViewRay’s MRIdian linac technology, the presentation of additional data at the ASTRO annual meeting in September, the recognition as revenue of the MRIdian System shipped in the second quarter of 2016 and ViewRay’s conference call to discuss its second quarter 2016 financial results. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue ViewRay’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize MRIdian linac technology, competition in the industry in which ViewRay operates and overall market conditions. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents ViewRay files with the SEC available at www.sec.gov.
Contact:
Investor Relations:
Ajay Bansal
Chief Financial Officer
1-844-MRIdian (674-3426)
Exhibit 99.1
Michael Saracen
Senior Director, Marketing
Phone: +1 440.703.3210, ext. 200
Email: [email protected]
Exhibit 99.1
VIEWRAY, INC.
Condensed Consolidated Statements of Operations
(In thousands, except share and per share data)
(Unaudited)
|
|
|
Three Months Ended June 30, |
|
|
Six Months Ended June 30, |
|
||||||||||
|
|
|
2016 |
|
|
2015 |
|
|
2016 |
|
|
2015 |
|
||||
|
Gross Orders |
|
$ |
17,100 |
|
|
$ |
— |
|
|
$ |
28,280 |
|
|
$ |
17,200 |
|
|
Backlog |
|
$ |
100,740 |
|
|
$ |
71,860 |
|
|
$ |
100,740 |
|
|
$ |
71,860 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
5,240 |
|
|
$ |
99 |
|
|
Service |
|
|
299 |
|
|
|
182 |
|
|
|
515 |
|
|
|
363 |
|
|
Total revenue |
|
|
299 |
|
|
|
182 |
|
|
|
5,755 |
|
|
|
462 |
|
|
Cost of revenue: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product |
|
|
139 |
|
|
|
391 |
|
|
|
6,066 |
|
|
|
545 |
|
|
Service |
|
|
724 |
|
|
|
442 |
|
|
|
1,325 |
|
|
|
1,065 |
|
|
Total cost of revenue |
|
|
863 |
|
|
|
833 |
|
|
|
7,391 |
|
|
|
1,610 |
|
|
Gross margin |
|
|
(564 |
) |
|
|
(651 |
) |
|
|
(1,636 |
) |
|
|
(1,148 |
) |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
|
2,964 |
|
|
|
2,258 |
|
|
|
6,363 |
|
|
|
4,506 |
|
|
Selling and marketing |
|
|
1,402 |
|
|
|
1,227 |
|
|
|
2,681 |
|
|
|
2,191 |
|
|
General and administrative |
|
|
5,788 |
|
|
|
7,174 |
|
|
|
12,108 |
|
|
|
11,497 |
|
|
Total operating expenses |
|
|
10,154 |
|
|
|
10,659 |
|
|
|
21,152 |
|
|
|
18,194 |
|
|
Loss from operations |
|
|
(10,718 |
) |
|
|
(11,310 |
) |
|
|
(22,788 |
) |
|
|
(19,342 |
) |
|
Interest income |
|
|
— |
|
|
|
— |
|
|
|
1 |
|
|
|
1 |
|
|
Interest expense |
|
|
(1,377 |
) |
|
|
(839 |
) |
|
|
(2,459 |
) |
|
|
(1,323 |
) |
|
Other income (expense), net |
|
|
(20 |
) |
|
|
(25 |
) |
|
|
(237 |
) |
|
|
35 |
|
|
Loss before provision for income taxes |
|
$ |
(12,115 |
) |
|
$ |
(12,174 |
) |
|
$ |
(25,483 |
) |
|
$ |
(20,629 |
) |
|
Provision for income taxes |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
Net loss attributable to common stockholders |
|
$ |
(12,115 |
) |
|
$ |
(12,174 |
) |
|
$ |
(25,483 |
) |
|
$ |
(20,629 |
) |
|
Net loss per share attributable to common stockholders, basic and diluted |
|
$ |
(0.32 |
) |
|
$ |
(13.24 |
) |
|
$ |
(0.67 |
) |
|
$ |
(22.52 |
) |
|
Weighted-average common shares used to compute net loss per share attributable to common stockholders, basic and diluted |
|
|
38,234,703 |
|
|
|
919,776 |
|
|
|
38,223,071 |
|
|
|
915,870 |
|
Exhibit 99.1
Condensed Consolidated Balance Sheets
(In thousands)
(Unaudited)
|
|
|
June 30, 2016 |
|
|
December 31, 2015 (1) |
|
||
|
|
|
(Unaudited) |
|
|
|
|
|
|
|
ASSETS |
|
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
9,429 |
|
|
$ |
20,667 |
|
|
Accounts receivable |
|
|
1,710 |
|
|
|
830 |
|
|
Inventory |
|
|
11,193 |
|
|
|
8,073 |
|
|
Deposits on purchased inventory |
|
|
2,877 |
|
|
|
3,936 |
|
|
Deferred cost of revenue |
|
|
7,545 |
|
|
|
8,782 |
|
|
Prepaid expenses and other current assets |
|
|
1,783 |
|
|
|
1,329 |
|
|
Total current assets |
|
|
34,537 |
|
|
|
43,617 |
|
|
Property and equipment, net |
|
|
12,238 |
|
|
|
7,306 |
|
|
Restricted cash |
|
|
943 |
|
|
|
943 |
|
|
Intangible assets, net |
|
|
120 |
|
|
|
200 |
|
|
Other assets |
|
|
31 |
|
|
|
91 |
|
|
TOTAL ASSETS |
|
$ |
47,869 |
|
|
$ |
52,157 |
|
|
LIABILITIES AND STOCKHOLDERS’ DEFICIT |
|
|
|
|
|
|
|
|
|
Current liabilities: |
|
|
|
|
|
|
|
|
|
Accounts payable |
|
$ |
5,957 |
|
|
$ |
4,358 |
|
|
Accrued liabilities |
|
|
5,154 |
|
|
|
5,413 |
|
|
Customer deposits |
|
|
11,950 |
|
|
|
12,763 |
|
|
Deferred revenue, current portion |
|
|
8,644 |
|
|
|
5,616 |
|
|
Total current liabilities |
|
|
31,705 |
|
|
|
28,150 |
|
|
Long-term debt, net |
|
|
44,135 |
|
|
|
29,016 |
|
|
Deferred revenue, net of current portion |
|
|
302 |
|
|
|
345 |
|
|
Other long-term liabilities |
|
|
2,812 |
|
|
|
1,603 |
|
|
TOTAL LIABILITIES |
|
|
78,954 |
|
|
|
59,114 |
|
|
Commitments and contingencies (Note 6) |
|
|
|
|
|
|
|
|
|
Preferred stock, par value $0.01 per share; 10,000,000 shares authorized at June 30, 2016 (unaudited) and December 31, 2015; no shares issued and outstanding at June 30, 2016 (unaudited) and December 31, 2015 |
|
|
— |
|
|
|
— |
|
|
Stockholders’ deficit: |
|
|
|
|
|
|
|
|
|
Common stock, par value of $0.01 per share; 300,000,000 shares authorized at June 30, 2016 (unaudited) and December 31, 2015; 38,362,134 and 38,204,960 shares issued and outstanding at June 30, 2016 (unaudited) and December 31, 2015 |
|
|
374 |
|
|
|
372 |
|
|
Additional paid-in capital |
|
|
191,065 |
|
|
|
189,712 |
|
|
Accumulated deficit |
|
|
(222,524 |
) |
|
|
(197,041 |
) |
|
TOTAL STOCKHOLDERS’ DEFICIT |
|
|
(31,085 |
) |
|
|
(6,957 |
) |
|
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT |
|
$ |
47,869 |
|
|
$ |
52,157 |
|
(1) The condensed consolidated balance sheet as of December 31, 2015 was derived from audited financial statements as of that date.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ChainIT Announces Strategic Partnership with excelerated to Strengthen Supplier Compliance and Final-Mile Supply Chain Visibility
- Dingdong to Report Second Quarter 2026 Financial Results on August 20, 2026
- OmniAb Raises 2026 Financial Guidance
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
